Back to Global NewsPublished: 27 Feb 2026Download AppJoin TelegramWhy uniQure's 32% Crash Signals a Rare‑Disease Approval Storm#uniQure#gene therapy#FDA#rare diseases#investment#AMT-130#RegenxbioDownload AppJoin CommunityShare Article